17 recruiting, 11 not yet recruiting, 6 active not recruiting, 4 completed. 12 Phase 2, 7 Not applicable, 6 Phase 3, 5 Early Phase 1, 3 Phase 1.
Follow IgA Nephropathy (IgAN): new trials by email Literature Review of IgA Nephropathy (IgAN) trials Research Report on IgA Nephropathy (IgAN)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy | Early Phase 1 | Not yet recruiting | Grit Biotechnology | 30 | 2027-08-01 | 2026-09-11 |
| A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy zigakibart, atrasentan, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Not yet recruiting | Novartis Pharmaceuticals | 340 | 2026-12-01 | 2026-09-30 |
| A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy JADE101, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Recruiting | Jade Biosciences, Inc. | 480 | 2026-12-01 | 2026-11-03 |
| IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy IBI3034, Placebo, Telitacicept - IgA Nephropathy (IgAN) | Phase 1 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 100 | 2026-10-15 | 2026-10-21 |
| Mediators of Loin Pain in IgA Nephropathy IgA Nephropathy (IgAN) | Enrolling by invitation | University of Leicester | 40 | 2026-10-13 | 2026-10-20 | |
| Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN) atrasentan - IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN) | Phase 4 | Not yet recruiting | University of Illinois at Chicago | 20 | 2026-09-29 | 2026-09-21 |
| Universal STAR-T Cell Injection in Autoimmune Kidney Diseases Universal STAR-T Cell - IgA Nephropathy (IgAN), Primary Membranous Nephropathy | Not applicable | Not yet recruiting | Guangdong Provincial People's Hospital | 24 | 2026-08-31 | 2026-08-10 |
| To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies Gd-IgA1 monitoring - IgA Nephropathy (IgAN), Henoch Schönlein Purpura Nephritis | Not applicable | Recruiting | Hong Zhang | 374 | 2026-08-24 | 2026-09-16 |
| Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy NEFECON, Placebo - IgA Nephropathy (IgAN) | Phase 4 | Recruiting | Nanfang Hospital, Southern Medical University | 288 | 2026-06-23 | 2026-09-02 |
| Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy sparsentan - IgA Nephropathy (IgAN) | Not yet recruiting | Waid City Hospital, Zurich | 50 | 2026-06-01 | 2026-04-29 | |
| SLN12140 in Adult Participants With IgA Nephropathy in China SLN12140, Placebo - IgA Nephropathy (IgAN) | Phase 2 | Not yet recruiting | Linno Pharmaceuticals, Inc. | 48 | 2026-05-29 | 2026-04-28 |
| Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases EVER001 - Minimal Change Disease (MCD), IgA Nephropathy (IgAN) | Phase 2 | Recruiting | Everest Medicines (China) Co.,Ltd. | 45 | 2026-05-20 | 2026-08-05 |
| CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease QT-219CX - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Early Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2026-05-08 | 2026-05-14 |
| Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy CD19 CAR-γδ T cell - Membranous Nephropathy, Lupus Nephritis (LN) | Early Phase 1 | Not yet recruiting | Air Force Military Medical University, China | 15 | 2026-05-01 | 2026-04-16 |
| Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN HSK39297, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 370 | 2026-04-07 | 2026-05-28 |
| Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease UCAR T-cell - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Early Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2026-04-01 | 2026-04-02 |
| A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment RG002C0106 - Renal Impairments, IgA Nephropathy (IgAN) | Phase 1 | Active not recruiting | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | 24 | 2026-03-15 | 2026-10-15 |
| Autoimmune Protocol Diet Intervention on Proteinuria in IgA Nephropathy Patients Low inflammation diet intervention - IgA Nephropathy (IgAN) | Not applicable | Withdrawn | University of California, Los Angeles | 2026-02-01 | 2026-07-27 | |
| The Randomized Controlled Study of Shenqi Yishen Granules in the Treatment of IgA Nephropathy Shenqi Yishen Granules, Placebo - IgA Nephropathy (IgAN) | Not applicable | Not yet recruiting | Keda Lu | 102 | 2026-01-01 | 2026-01-22 |
| CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease UCAR T-cell - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2025-12-01 | 2026-02-03 |
Showing 20 of 43. Sign in to see all of them.
Glomerulonephritis, IGA (43) · Autoimmune Diseases (4) · Glomerulonephritis, Membranous (4) · Kidney Diseases (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Nephrotic Syndrome (3) · Proteinuria (3) · Scleroderma, Systemic (3) · Diabetic Nephropathies (2) · Glomerulosclerosis, Focal Segmental (2) · Renal Insufficiency, Chronic (2) · Urologic Diseases (2) · Fibrosis (1) · Flank Pain (1) · Glomerulonephritis (1)
Female Urogenital Diseases (43) · Female Urogenital Diseases and Pregnancy Complications (43) · Male Urogenital Diseases (43) · Glomerulonephritis (42) · Immune System Diseases (42) · Nephritis (42) · Urogenital Diseases (42) · Urologic Diseases (41) · Autoimmune Diseases (39) · Kidney Diseases (39) · Pathological Conditions, Signs and Symptoms (7) · Skin and Connective Tissue Diseases (5) · Connective Tissue Diseases (4) · Nephrosis (4) · Signs and Symptoms (4)
telitacicept (4) · Atrasentan (2) · Methylprednisolone (2) · Prednisolone (2) · Prednisone (2) · TACI receptor-IgG Fc fragment fusion protein (2) · Adrenal Cortex Hormones (1) · Angiotensin Receptor Antagonists (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Glucocorticoids (1) · Independent Medical Evaluation (1) · Irbesartan (1) · Mycophenolic Acid (1) · Pharmaceutical Preparations (1) · Surveys and Questionnaires (1)
Haisco Pharmaceutical Group Co., Ltd. (3) · The Children's Hospital of Zhejiang University School of Medicine (3) · Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. (2) · Vera Therapeutics, Inc. (2) · ADARx Pharmaceuticals, Inc. (1) · Air Force Military Medical University, China (1) · Alnylam Pharmaceuticals (1) · Assistance Publique - Hôpitaux de Paris (1) · Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari (1) · Biocity Biopharmaceutics Co., Ltd. (1) · Botkin Hospital (1) · Everest Medicines (China) Co.,Ltd. (1) · Grit Biotechnology (1) · Guangdong Provincial People's Hospital (1) · Guixia Ding (1)
China (27) · United States (7) · United Kingdom (3) · France (2) · Italy (2) · Spain (2) · Taiwan (2) · Australia (1) · Canada (1) · Hong Kong (1) · Malaysia (1) · Philippines (1) · Russia (1) · Singapore (1) · South Korea (1)
Anand Srivastava, MD, MPH (1) · Arezoo Mirad, MD (1) · Eric Michael, MD (1) · Fernando Fervenza, MD (1) · Haresh Selvaskandan, MBChB, MRCP, MRes, PhD (1) · Hong Zhang, PH.D. (1) · Li Li, MD (1) · Loreto Gesualdo, MD (1) · Nabeel Aslam, MD (1) · Zeeshan Khawaja (1) · Zhihong Liu, Master (1)
2018 (1)